Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

about

Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

Item

http://www.wikidata.org/entity/Q39187952

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

@en

Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

@nl

type

Item

label

Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

@en

Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

@nl

prefLabel

Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

@en

Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

@nl

P1476

Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.

@en

P2093

Francisco Marín

http://www.w3.org/2001/XMLSchema#string

Gonzalo Barón-Esquivias

http://www.w3.org/2001/XMLSchema#string

Marcelo Sanmartín Fernandez

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized, controlled trials, observational studies, and the hierarchy of research designs

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.

Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry

Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.

Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.

P304

403-413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14779072.2017.1309293

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marcelo Sanmartin

Gonzalo Barón-Esquivias

Francisco Marín

P577

2017-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28319424

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation